NovoCure

TTFields Will Lead Oncological Advancements For Aging Populations

AnalystHighTarget

Not Invested

Community Contributor

Published

04 Aug 25

Updated

14 Dec 25

Views

n/a

AnalystHighTarget's Fair Value

n/a

-58.3%

-3.6%

-58.3%

-3.6%

You can edit this narrative until Dec 15 11:05 AM. Then, changes will post as Updates.

Author's Valuation

US$41.2568.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on 14 Dec 25

Fair value Increased 8.55%

NVCR: Long-Term Pipeline And Margin Outlook Will Support Upside Potential

Analysts have modestly raised their fair value estimate for NovoCure from $38.00 to about $41.25 per share, reflecting updated models that balance increased long term conservatism with slightly stronger profit margin expectations and a higher future earnings multiple. Analyst Commentary Analyst sentiment on NovoCure remains mixed, but recent updates show a constructive undertone even as some models become more conservative.

AnalystHighTarget Fair Value

US$41.25

68.9% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

8.42%

Medical Equipment revenue growth rate

6.86%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.55%

Calculation

US$113.54m

Earnings '28

54.70x

PE Ratio '28

US$6.21b

Market Cap '28

US$6.21b

Market Cap '28

118.42m

No. shares '28

US$52.45

Share Price '28

US$52.45 Share Price '28

Discounted to 2025 @ 8.46% p.a.

US$41.11

Fair Value '25